• Blueprint Medicines average return on tangible equity for 2023 was -141.14, a 87.91% decline from 2022.
• Blueprint Medicines average return on tangible equity for 2022 was -75.11, a 889.59% increase from 2021.
• Blueprint Medicines average return on tangible equity for 2021 was -7.59, a 50.39% increase from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.